Guardant Health, Inc. $GH Stock Holdings Increased by Sicart Associates LLC

Sicart Associates LLC lifted its stake in Guardant Health, Inc. (NASDAQ:GH) by 39.1% in the third quarter, HoldingsChannel reports. The firm owned 230,083 shares of the company’s stock after acquiring an additional 64,628 shares during the quarter. Guardant Health makes up about 3.9% of Sicart Associates LLC’s investment portfolio, making the stock its 5th biggest position. Sicart Associates LLC’s holdings in Guardant Health were worth $14,376,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Signaturefd LLC raised its holdings in Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after acquiring an additional 213 shares in the last quarter. American Century Companies Inc. increased its position in shares of Guardant Health by 0.3% in the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock valued at $4,439,000 after purchasing an additional 282 shares during the last quarter. IFP Advisors Inc lifted its position in shares of Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares during the last quarter. Main Management ETF Advisors LLC increased its holdings in Guardant Health by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 21,257 shares of the company’s stock valued at $1,106,000 after buying an additional 348 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in Guardant Health by 0.9% in the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock valued at $2,177,000 after buying an additional 469 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GH. Cowen reiterated a “buy” rating on shares of Guardant Health in a report on Thursday, October 30th. Wolfe Research upgraded shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target on the stock in a research note on Thursday, September 25th. Morgan Stanley boosted their price objective on shares of Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Piper Sandler upped their target price on shares of Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Finally, Barclays increased their target price on shares of Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday. Twenty-three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $94.57.

Guardant Health Trading Down 2.6%

GH stock opened at $100.00 on Wednesday. The company has a market capitalization of $12.60 billion, a P/E ratio of -31.15 and a beta of 1.58. The business has a 50 day simple moving average of $90.23 and a 200-day simple moving average of $66.58. Guardant Health, Inc. has a twelve month low of $29.91 and a twelve month high of $112.43.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.88) earnings per share. Research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Michael Brian Bell sold 80,362 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $103.14, for a total value of $8,288,536.68. Following the transaction, the chief financial officer owned 28,052 shares in the company, valued at $2,893,283.28. The trade was a 74.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.05, for a total value of $10,505,000.00. Following the sale, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at $17,671,826.15. The trade was a 37.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 330,531 shares of company stock valued at $34,526,719. 6.10% of the stock is owned by insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.